Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$308.78 +0.3%	$271.78	$152.30 ▼ $310.22	$40.26B	0.22	931,893 shs	520,199 shs
BGNE BeiGene		$194.32	$141.31 ▼ $248.16	$18.03B	0.57	323,752 shs	331,608 shs
BMRN BioMarin Pharmaceutical	$56.24 +0.0%	$59.11	$52.93 ▼ $94.85	$10.79B	0.19	1.83 million shs	1.57 million shs
GMAB Genmab A/S	$22.86 +0.2%	$20.65	$17.24 ▼ $28.56	$14.66B	0.96	1.17 million shs	1.62 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+2.38%	+7.95%	+21.68%	+92.03%
BGNE BeiGene	0.00%	0.00%	0.00%	0.00%	+13.61%
BMRN BioMarin Pharmaceutical	0.00%	-0.76%	-5.15%	-21.43%	-32.68%
GMAB Genmab A/S	0.00%	+2.79%	+14.79%	+9.71%	-12.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	4.243 of 5 stars	2.4	5.0	0.0	4.3	3.4	2.5	0.6
BGNE BeiGene	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	4.9308 of 5 stars	3.4	5.0	0.0	3.3	2.9	2.5	3.8
GMAB Genmab A/S	3.8425 of 5 stars	3.3	5.0	0.0	0.0	2.5	0.0	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.77	Moderate Buy	$319.58	3.50% Upside
BGNE BeiGene	2.83	Moderate Buy	$253.92	∞ Upside
BMRN BioMarin Pharmaceutical	2.74	Moderate Buy	$93.45	66.17% Upside
GMAB Genmab A/S	2.69	Moderate Buy	$39.17	71.33% Upside

Current Analyst Ratings Breakdown

Latest BGNE, BMRN, ALNY, and GMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$330.00 ➝ $338.00
5/5/2025	BMRN BioMarin Pharmaceutical	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$124.00 ➝ $104.00
5/2/2025	ALNY Alnylam Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$331.00 ➝ $349.00
5/2/2025	ALNY Alnylam Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$300.00 ➝ $325.00
5/2/2025	BMRN BioMarin Pharmaceutical	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$82.00 ➝ $78.00
4/11/2025	ALNY Alnylam Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$284.00 ➝ $268.00
4/9/2025	ALNY Alnylam Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$320.00 ➝ $320.00
4/9/2025	GMAB Genmab A/S	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $37.00
4/2/2025	ALNY Alnylam Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$500.00 ➝ $500.00
4/1/2025	GMAB Genmab A/S	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform ➝ Underperform
3/31/2025	ALNY Alnylam Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$338.00 ➝ $342.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.35B	17.15	N/A	N/A	$0.52 per share	593.81
BGNE BeiGene	$3.32B	0.00	N/A	N/A	$37.10 per share	0.00
BMRN BioMarin Pharmaceutical	$2.95B	3.66	$2.66 per share	21.17	$29.69 per share	1.89
GMAB Genmab A/S	$3.12B	4.71	$1.54 per share	14.80	$8.04 per share	2.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.09	N/A	346.94	N/A	-12.37%	N/A	-6.83%	7/30/2025 (Estimated)
BGNE BeiGene	-$881.71M	-$8.24	N/A	N/A	N/A	-25.94%	-25.12%	-14.95%	N/A
BMRN BioMarin Pharmaceutical	$167.65M	$2.69	25.56	12.90	0.61	14.96%	9.91%	7.65%	8/4/2025 (Estimated)
GMAB Genmab A/S	$1.14B	$1.76	13.14	12.84	2.65	36.30%	16.78%	13.79%	8/14/2025 (Estimated)

Latest BGNE, BMRN, ALNY, and GMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.23	$0.31	+$0.08	$0.31	$5.17 billion	$715.00 million
5/1/2025	Q1 2025	ALNY Alnylam Pharmaceuticals	-$0.37	-$0.44	-$0.07	-$0.44	$584.32 million	$594.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BGNE BeiGene	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	15.27	2.78	2.71
BGNE BeiGene	0.05	1.93	1.72
BMRN BioMarin Pharmaceutical	0.11	5.33	2.62
GMAB Genmab A/S	N/A	5.25	5.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BGNE BeiGene	48.55%
BMRN BioMarin Pharmaceutical	98.71%
GMAB Genmab A/S	7.07%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.50%
BGNE BeiGene	7.43%
BMRN BioMarin Pharmaceutical	0.85%
GMAB Genmab A/S	1.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,000	130.39 million	127.52 million	Optionable
BGNE BeiGene	9,000	97.62 million	90.20 million	Optionable
BMRN BioMarin Pharmaceutical	3,080	191.78 million	187.06 million	Optionable
GMAB Genmab A/S	1,660	641.22 million	651.58 million	Optionable

BGNE, BMRN, ALNY, and GMAB Headlines

Recent News About These Companies

Transactions in Connection with Share Buy-back Program

June 16 at 9:28 AM | globenewswire.com

Park Avenue Securities LLC Takes Position in Genmab A/S (NASDAQ:GMAB)

June 16 at 3:23 AM | marketbeat.com

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

June 15 at 5:00 AM | globenewswire.com

June 15 at 5:00 AM | businesswire.com

Genmab A/S (NASDAQ:GMAB) Stock Rating Lowered by Wall Street Zen

June 14 at 1:57 AM | marketbeat.com

Genmab A/S (NASDAQ:GMAB) Given Consensus Recommendation of "Moderate Buy" by Brokerages

June 13 at 2:41 AM | americanbankingnews.com

Genmab A/S (NASDAQ:GMAB) Given Consensus Rating of "Moderate Buy" by Analysts

June 13 at 2:40 AM | marketbeat.com

Grant of Restricted Stock Units and Warrants to Employees in Genmab

June 12, 2025 | globenewswire.com

Transactions in Connection with Share Buy-back Program

June 10, 2025 | globenewswire.com

Genmab A/S (NASDAQ:GMAB) Downgraded to "Hold" Rating by Wall Street Zen

June 8, 2025 | americanbankingnews.com

Genmab A/S (NASDAQ:GMAB) Downgraded to Hold Rating by Wall Street Zen

June 7, 2025 | marketbeat.com

Genmab A/S (NASDAQ:GMAB) Shares Gap Down - Should You Sell?

June 3, 2025 | marketbeat.com

Genmab A/S (NASDAQ:GMAB) Shares Gap Up - What's Next?

June 3, 2025 | marketbeat.com

Genmab advances with lower dose of Rina-S in endometrial cancer trials

June 3, 2025 | investing.com

Why Genmab Stock Smashed It on Monday

June 2, 2025 | finance.yahoo.com

Genmab Announces Investigational Rinatabart Sesutecan (Rina-SÂ®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOLâ„¢-01 Trial

June 2, 2025 | businesswire.com

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

June 2, 2025 | globenewswire.com

Transactions in Connection with Share Buy-back Program

June 2, 2025 | globenewswire.com

Legacy Wealth Asset Management LLC Purchases 13,246 Shares of Genmab A/S (NASDAQ:GMAB)

June 2, 2025 | marketbeat.com

33,010 Shares in Genmab A/S (NASDAQ:GMAB) Bought by Mackenzie Financial Corp

June 2, 2025 | marketbeat.com

Genmab A/S (NASDAQ:GMAB) Shares Acquired by Squarepoint Ops LLC

May 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGNE, BMRN, ALNY, and GMAB Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$308.78 +0.79 (+0.26%)

Closing price 04:00 PM Eastern

Extended Trading

$308.92 +0.14 (+0.04%)

As of 07:47 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

BeiGene NASDAQ:BGNE

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

BioMarin Pharmaceutical NASDAQ:BMRN

$56.24 +0.02 (+0.04%)

Closing price 04:00 PM Eastern

Extended Trading

$55.88 -0.37 (-0.65%)

As of 05:51 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Genmab A/S NASDAQ:GMAB

$22.86 +0.04 (+0.18%)

Closing price 04:00 PM Eastern

Extended Trading

$22.86 +0.00 (+0.02%)

As of 05:18 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time